Nomura Holdings
MLYS icon

Nomura Holdings’s Mineralys Therapeutics MLYS Stock Holding History

Nomura Holdings’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$542K Buy
+20,000
New +$587K ﹤0.01% 1339

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Nomura Holdings's MLYS Position: Q1 2026 in Review

Nomura Holdings opened a new position in Mineralys Therapeutics (MLYS) in Q1 2026: 20,000 shares worth $542K. The stake represents ﹤0.01% of the portfolio and ranks #1339 among its holdings.

214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Nomura Holdings held 20,000 shares of Mineralys Therapeutics worth $542K as of Q1 2026.
  • Mineralys Therapeutics was a new Nomura Holdings position in Q1 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Nomura Holdings's portfolio in Q1 2026, its #1339 holding.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.